von Tirpitz Christian, Reinshagen Max
Department of Medicine I, University of Ulm, Germany.
Eur J Gastroenterol Hepatol. 2003 Aug;15(8):869-76. doi: 10.1097/00042737-200308000-00006.
Osteoporosis is a frequent complication in the course of various gastrointestinal disorders. Since its pathogenesis is complex, and incompletely understood in comparison to the well-known pathomechanism of postmenopausal osteoporosis, adequate management is difficult. We first summarize those therapeutic options which have strong evidence in postmenopausal osteoporosis and, thereafter, we review those in the context of different gastrointestinal diseases. Treatment of the underlying intestinal disorder seems to be most important to normalise altered bone metabolism and to prevent osteoporosis in patients with coeliac disease. In patients with osteoporosis associated with Crohn's disease, various treatment strategies (such as vitamin D, sodium fluoride, bisphosphonates) are discussed. In contrast to postmenopausal osteoporosis, interventional studies in secondary osteoporosis are often limited by the small study population and data about the efficacy of any treatment in prevention of fractures are therefore lacking. Well-conducted, controlled studies with the endpoint of preventing fractures are therefore required to optimise the treatment of osteoporosis in these patients.
骨质疏松症是各种胃肠道疾病过程中常见的并发症。由于其发病机制复杂,与广为人知的绝经后骨质疏松症的发病机制相比尚未完全明确,因此难以进行充分的管理。我们首先总结那些在绝经后骨质疏松症中有充分证据的治疗选择,然后,我们在不同胃肠道疾病的背景下对这些治疗选择进行综述。治疗潜在的肠道疾病似乎对于使骨代谢改变正常化以及预防乳糜泻患者的骨质疏松症最为重要。对于与克罗恩病相关的骨质疏松症患者,讨论了各种治疗策略(如维生素D、氟化钠、双膦酸盐)。与绝经后骨质疏松症不同,继发性骨质疏松症的干预性研究往往受限于研究人群规模较小,因此缺乏关于任何治疗预防骨折疗效的数据。因此,需要开展以预防骨折为终点的精心设计的对照研究,以优化这些患者的骨质疏松症治疗。